Previous 10 | Next 10 |
home / stock / drug / drug articles
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD A decade after it was founded as a wholly-owned ...
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Results of a first-in-class clinical trial on ibogaine-magnesium th...
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Results of a first-in-class clinical trial on ibogaine-magnesium th...
Biden To Decide On Psychedelic Therapy Bill President Joe Biden received the final version of a large-scale defense bill providing funding for psyc...
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy The world seemed to come to a momentary ...
Defense Dept. Funds Ketamine Study For PTSD Treatment A DOD Health Agency-funded adaptive platform trial for alternative treatments for ...
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Vivek Ramaswamy, who famously said he did no...
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? An average of 17 veterans committed suicide per day in 2020...
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court The U.S. Court of Appeals for the Ninth Circuit ruled against the Drug Enforc...
News, Short Squeeze, Breakout and More Instantly...
Bright Minds Biosciences Inc. Company Name:
DRUG Stock Symbol:
NASDAQ Market:
Bright Minds Biosciences Inc. Website:
Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...
Bright Minds Biosciences Inc. (DRUG) is expected to report for quarter end 2023-12-31